Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pleuropulmonary changes induced by ergoline drugs

P Pfitzenmeyer1, P Foucher, G Dennewald

  • 1Services de Gériatrie, Centre Hospitalier Universitaire, Faculté de Médecine et Université de Bourgogne, Dijon, France.

The European Respiratory Journal
|May 1, 1996
PubMed
Summary

Ergolines like nicergoline and dihydroergotamine can cause chronic pleural thickening. Dihydroergocristine may induce reversible interstitial pneumonitis. Both conditions improve after discontinuing the medication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
Same author

[Adherence to lung cancer screening by low-dose chest CT: Results of the first round of screening in the Multicenter Interventional DeCanPHaR Study].

Revue des maladies respiratoires·2026
Same author

Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

ESMO open·2025
Same author

Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer.

Respiratory medicine and research·2024
Same author

COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study.

Respiratory medicine and research·2024

Area of Science:

  • Pulmonology
  • Clinical Pharmacology
  • Toxicology

Background:

  • Ergolines are known to cause chronic pleuropneumonitis.
  • This study investigates pleuropulmonary changes associated with other ergoline derivatives.

Purpose of the Study:

  • To report on pleuropulmonary complications in patients treated with nicergoline, dihydroergocristine, and dihydroergotamine.
  • To review the literature on ergoline-induced pleuropulmonary changes.

Main Methods:

  • Retrospective case study (1985-1995) of eight patients.
  • Review of clinical data, radiological imaging (CT scans), pulmonary function tests, bronchoalveolar lavage, and histopathology.
  • Literature review of ergoline-induced pleuropulmonary changes.

Related Experiment Videos

Main Results:

  • Eight patients developed pleuropulmonary changes on nicergoline, dihydroergocristine, or dihydroergotamine.
  • Bibasilar pleural thickening with or without effusion occurred in six patients.
  • Interstitial pneumonitis, reversible upon drug withdrawal, was seen in two patients on dihydroergocristine.

Conclusions:

  • Nicergoline and dihydroergotamine can induce chronic pleural thickening/effusion, which slowly resolves after drug cessation.
  • Dihydroergocristine can cause reversible interstitial pneumonitis.
  • Pleuropulmonary changes associated with these ergolines generally show favorable outcomes after discontinuation.